Goldman Sachs
TRVI icon

Goldman Sachs’s Trevi Therapeutics TRVI Stock Holding History

Goldman Sachs’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6M Buy
1,227,772
+170,881
+16% +$1.91M ﹤0.01% 2744
2025
Q4 		$13.2M Buy
1,056,891
+269,437
+34% +$3.11M ﹤0.01% 2798
2025
Q3 		$7.21M Buy
787,454
+488,409
+163% +$3.66M ﹤0.01% 3299
2025
Q2 		$1.64M Buy
299,045
+87,172
+41% +$542K ﹤0.01% 4333
2025
Q1 		$1.33M Sell
211,873
-24,271
-10% -$116K ﹤0.01% 4478
2024
Q4 		$973K Buy
236,144
+71,906
+44% +$230K ﹤0.01% 4842
2024
Q3 		$549K Buy
164,238
+91,045
+124% +$271K ﹤0.01% 5002
2024
Q2 		$218K Buy
73,193
+35,219
+93% +$97.9K ﹤0.01% 5227
2024
Q1 		$131K Buy
37,974
+14,059
+59% +$31.4K ﹤0.01% 5199
2023
Q4 		$32K Sell
23,915
-2,235
-9% -$3.38K ﹤0.01% 5421
2023
Q3 		$57K Sell
26,150
-8,901
-25% -$20.1K ﹤0.01% 5263
2023
Q2 		$83.8K Buy
+35,051
New +$88.3K ﹤0.01% 5386

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Goldman Sachs's TRVI Position: Q1 2026 in Review

Goldman Sachs increased its Trevi Therapeutics (TRVI) stake by 16% in Q1 2026, buying an estimated $1.91M and bringing the position to 1,227,772 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

Goldman Sachs first reported a position in TRVI in Q2 2023 and has held it in 12 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Goldman Sachs held 1,227,772 shares of Trevi Therapeutics worth $14.6M as of Q1 2026.
  • Goldman Sachs bought 170,881 Trevi Therapeutics shares in Q1 2026, an estimated $1.91M.
  • Trevi Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2744 holding.
  • Goldman Sachs first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.